Latest News

David Gruen, MD, MBA, FACR, of Advanced Radiology Consultants, shares how leading programs turned clinical evidence into operational reality.

What's already being done with large language models in radiology practice today.

Preoperative use of (68Ga)Ga-FAPI-46 PET/CT demonstrated an 81 percent intraclass correlation coefficient (ICC) with the intraoperative peritoneal cancer index (PCI) in comparison to 76 percent for MRI and 54 percent for (18F)FDG PET/CT (FDG PET), according to new research presented at the SNMMI conference.

The proportion of breast cancer potentially flagged by three different AI algorithms 10 years prior to diagnosis ranged between 12.7 to 17 percent, according to newly published retrospective research.

Use of the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide led to a > 30 percent reduction in liver fat content in nearly 85 percent of obese patients with at-risk MASLD, according to MRI findings in new phase 3 research.

Are you on the right path to financial independence and retiring early?

Catch up on a variety of new FDA clearances in radiology from the past week.

Catch up on the top radiology content of the past week.

While researchers saw no significant difference in metastasis-free survival with the use of perioperative apalutamide in patients undergoing radical prostatectomy based on conventional imaging alone, the addition of PSMA PET imaging revealed a 20 percent higher likelihood of metastasis-free survival with adjunctive apalutamide.

In comparison to short-axial field of view PET/CT scanners, a total body PET/CT imaging platform with a long axis field of view detected more lesions in 68 percent of patients while reducing scan times by 83 percent, according to new research presented at the SNMMI conference.

In a recent interview, Phillip Kuo, MD, discussed new comparative multicenter prospective research, presented at the SNMMI conference, examining the urinary radioactivity of two PSMA PET radiotracers 18F-piflufolastat and 18F-flotufolastat.

Prior vaccination for prostate cancer-specific antigens was associated with more than double the rate of two-year overall survival in patients with mCRPC who were treated with 177Lu-PSMA-617, according to new research presented at the SNMMI conference.

Preliminary research findings, presented at the SNMMI conference, suggest that the alpha-emitting radioconjugate ATNM-400 may be a viable alternative for treating PCa that is resistant to androgen receptor pathway inhibitors (ARPIs).